All News

ANCA_5.jpg

Long-Term Rituximab in ANCA-Associated Vasculitis

Jack Cush, MD

The Annals of Internal Medicine reports that biannual rituximab infusions over 18 months was effective at maintaining remission in patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV).

Read Article
Plaquenil.HCQ_.pills_.jpg (keep)

Fighting Hydroxychloroquine Misinformation

Jack Cush, MD

JAMA Internal Medicine has posted an Editor's note on the use of hydroxychloroquine for COVID-19; noting the sequence of dysfunction since the president promoted its use on March 21, 2020, when he said “What do you have to lose? I’ll say it again: What do you have to lose? Take it.”.

Read Article
podcast logo

RheumNow Podcast – COVID-19 Responds to Steroids (7.24.20)

Jack Cush, MD

Dr. Jack Cush reviews the News and Journal Reports from the past week on RheumNow.com.

Read Article
labs2.jpg

Low Risk of COVID in Biologic Treated Rheum Patients

Jack Cush, MD

In an Annals of Rheumatic Disease report, Italian investigators performed consecutive testing for SARS-CoV-2 (IgM and IgG) between 25 March to 25 May 2020 and compared test results between rheumatic disease (RMD) patients and the general population. 

Read Article
FINAL 2020 Podcast Graphic

RheumNow Podcast – LTF – Listen to Fauci (7.17.20)

Jack Cush, MD

Dr. Jack Cush reviews the news, tweets and journal articles from the past week on RheumNow. Let's dig into this week's 14 highlights.

Read Article
heart.EKG_.CVD_.jpg

HCQ May Help Prevent Fetal Heart Block

RheumNow

Hydroxychloroquine (HCQ) helped reduce recurrent maternal autoantibody-mediated congenital heart block (CHB) in fetuses, an open-label study suggested.

Read Article
BMS has announced deucravacitinib: the generic name for its Tyk2 inhibitor (BMS-986165) - 15 long makes it a new rheum labeling record. It's being studied in Psoriatic arthritis, psoriasis, lupus and inflammatory bowel disease. https://t.co/E2x2lelktO

Links:

Dr. John Cush RheumNow ( View Tweet)

Sleep is a problem in Lupus! Metanalysis of 18 studies (n=1086) shows #SLE has lower sleep quality - The main problems being daytime dysfunction (WMD 0.64), subjective sleep quality (WMD 0.62) & habitual sleep efficiency (WMD  0.54) https://t.co/odSdm4E9iW

Links:

Dr. John Cush RheumNow ( View Tweet)

Full read clinical practice guideline on obesity management from the Canadian Medical Assn Journal. https://t.co/YdbjtnBcST

Links:

Dr. John Cush RheumNow ( View Tweet)

Virtual Video Joint Exam Pearl #3: Despite cam setups designed to do upper extremity exams, patients can easily move cams and limbs to examine spinal movt, gait, knee, ankle and foot problems with great accuracy.

Dr. John Cush RheumNow ( View Tweet)

A large Latin American SLE cohort was studied; 66 (5.6%) had familial SLE & 1110 (94.4%) sporadic SLE: Familial SLE was more often associated with discoid LE (OR 1.97) & CNS dz (OR 1.65), more MSK Dz. No group difference in Disease activity https://t.co/4Lak2q4QJn

Links:

Dr. John Cush RheumNow ( View Tweet)

Spanish registry of 3679 SLE pts finds 13.6% had polyautoimmunity (SLE plus another autoimmune Dz), Dx as thyroiditis (8%), Sjogrens (14%) secondary APS (14%). Incr odds in female, w/ ILD, Raynauds, SSA/SSB/RNP but LESS w/ antimalarial drugs [0.50] https://t.co/duTqepvmLR

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA recommends health care professionals discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder. Naloxone can be administered(+/- medical training) to help reduce opioid overdose deaths https://t.co/9B0hPhOm57

Links:

Dr. John Cush RheumNow ( View Tweet)

Belimumab FDA approved in kids (same dose 10mg/kg/IV) based on PLUTO trial - 93 SLE pts Rx w/ BEL or PBO. By wk 52, BEL had more SRI4 responders (52.8% vs 43.6%; OR 1.49;95% CI 0.64 to 3.46), more PRINTO/ACR 30 or 50 w/ stable PK. https://t.co/1xX0VLgl4q

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA has issued draft guidance on Cannibis research: “Cannabis & Cannabis-Derived Compounds: Quality Considerations for Clinical Research, Draft Guidance for Industry,” outlines FDA’s current thinking on clinical research related cannabis-derived compounds https://t.co/ppvisN1oxU

Links:

Dr. John Cush RheumNow ( View Tweet)

Aurinia Announces U.S. Food and Drug Administration Acceptance of the Filing of New Drug Application and Priority Review for Voclosporin for the Treatment of Lupus Nephritis https://t.co/BMgqvuAUP5

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is Up! Listen to Fauci! Watch it here>> https://t.co/dHq3fP85Ip or Listen to the Podcast>> https://t.co/LdHO7fKUCp

Links:

Dr. John Cush RheumNow ( View Tweet)

Retrospective study of 603 myositis (IIM), 4047 RA and 4061 controls shows IIM has higher risk of CV events (HR 1.38) and MI [HR 1.61] but not CVA [HR 0.92]. The CV risk in IIM was equal to that in RA [HR 1.01]. IIM CV risk only present 1st 5 years https://t.co/EyD3GHv2YY

Links:

Dr. John Cush RheumNow ( View Tweet)

The preliminary #ACR20 schedule is here! Along with all your favorite plenary and networking sessions, the program will feature #Rheumatologist Dr. Anthony Fauci giving us a live update on #COVID19. @ACRheum #ACRConvergence - Where Rheumatology Meets https://t.co/IWbiVw9PSP

Links:

Victoria Shanmugam VickiShanmugam ( View Tweet)

Ghent Univ experience and literature review shows that diffuse and localized scleroderma occurs in 2.4 to 7.4% often with Raynauds (6/8), scleroderma pattern on nailfold videocapillaroscopy and SSc-specific autoantibodies https://t.co/zDgXsuKD3p

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×